SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense investor backlash following the abrupt cancellation of a major contract with Marvell, which was triggered by the CFO's alleged violation of a confidentiality agreement. The community is sharply divided between those calling for immediate leadership changes to restore credibility and those attempting to buy the dip, citing the company's underlying photonics technology as a reason for long-term optimism.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is trending as a momentum-driven play, with investors closely watching for signs of a short squeeze amid high volatility and active sentiment regarding potential price swings. The community is heavily focused on the stock's thin float and the influence of speculative trading patterns, frequently comparing its aggressive moves to previous market runners.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors digest a major proposed $835 million acquisition of European Lithium, a deal that aims to consolidate 100% ownership of the Tanbreez rare earth project and simplify the company's capital structure. The community is actively debating the potential for a short squeeze amidst high borrow fees and limited share availability, while long-term bulls remain focused on the company's strategic role in Western resource security.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it hits new record highs, fueled by intense institutional demand and optimistic sentiment surrounding its dominance in the AI infrastructure cycle. Investors are actively debating the sustainability of its multi-trillion-dollar valuation, with bulls pointing to fundamental growth while skeptics monitor for potential signs of overheating.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently under intense scrutiny from the community following the release of Phase 3 results for its CRISPR-based HAE therapy, which met primary and secondary endpoints but has sparked debate over efficacy compared to existing oral alternatives. Investors are actively discussing the stock's high short interest, the potential for a short squeeze, and concerns over future dilution via the company's ATM facility, leaving sentiment sharply divided between those betting on a long-term breakthrough and those wary of clinical and commercial risks.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing intense volatility and volume-driven interest as investors monitor a tight effective float and speculate on potential buyout scenarios or strategic partnerships. The community remains deeply divided, with bullish participants pointing to recent institutional accumulation and clinical data, while others express skepticism regarding management's communication history and the potential for near-term equity dilution.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors digest a massive strategic windfall from its stake in SpaceX and aggressive moves into specialized AI hardware development alongside industry partners. The community remains focused on the company's AI-driven cloud growth and its potential to capture long-term value through its dominant search ecosystem and diversified AI infrastructure investments.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas is seeing heightened activity following reports of the administration evaluating price floor mechanisms for critical minerals, fueling community debate over the companys role as a strategic domestic supply chain asset. While some investors are accumulating shares citing the project's long-term government and corporate backing, others are debating the impact of ongoing project execution risks and broader macro volatility.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is currently trending as investors weigh the potential of a massive stock buyback and dividend hike against persistent concerns regarding smartphone market headwinds and loss of key modem business. The community is actively debating whether the stock represents a deep-value opportunity for AI-driven edge computing or if it remains a value trap due to structural revenue risks.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently trending as a prominent infrastructure play in the AI hardware sector, with investors closely watching for earnings-driven volatility after the company's recent strategic collaborations, such as the AMD Helios platform partnership. The community is actively debating the company's valuation relative to its hyperscaler demand, with many focused on whether this quarter will trigger a major breakout or another round of consolidation as it navigates significant institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today?

Biodexa Pharmaceuticals shares are trading sharply higher Thursday afternoon after the company said it partnered with Syngene International.read more...

Biodexa Pharmaceuticals Stock Surges 69% Over Partnership With Syngene International

(RTTNews) - Shares of Biodexa Pharmaceuticals Plc (BDRX) are climbing about 69 percent on Thursday morning trading after it announced a partnership with Syngene International Ltd for the manufacture...

Energy Crunch Sparks Sector Rally and Hidden Players Stepping into the Spotlight

A powerful convergence of global energy disruption and emerging technology catalysts is reshaping pockets of the market, with select small-cap names ready to make moves. $SKYQ, $XERI, $KBLB, $TGNT, $BDRX, $COCP

Biodexa Promotes Fiona Sharp To CFO As Stephen Stamp Cedes Role To Become Only CEO

(RTTNews) - Biodexa Pharmaceuticals Plc (BDRX), a clinical stage biopharmaceutical company, Monday announced that it has promoted Fiona Sharp to Chief Financial Officer and Company Secretary...

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December.&nbsp;The Cardiff, UK-based company's stock surge followed the U.S. FDA granting its treatment eRapa a Fast Track designation.&nbsp;The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.&nbsp;FAP currently has no effective medical treatment, with the only option being surgical resection of the colon or rectum.The Fast Track designation aims to expedite the development and review of drugs targeting serious conditions with significant unmet medical needs.&nbsp;Biodexa's Phase 2 study of eRapa showed promising results, with a median 17% reduction in total polyp burden and a 75% non-progression rate at 12 months.&nbsp;In cohort 2, patients showed an even better response, with a 29% median reduction in polyp burden and an 89% non-progression rate.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BDRX_sentiment_and_message_volume_Feb_10_2beb98885a.png" alt="BDRX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>BDRX sentiment and message volume Feb 10 as of 1:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment turned 'extremely bullish,' with the stock soaring to the top 10 trending symbols. The volume of messages spiked to its highest level in a year, reflecting increased excitement among investors.&nbsp;Users were optimistic about the stock's potential, with one commenting that it could hit $10 and another suggesting that it was a "last chance to buy in before it goes above $8."&nbsp;<stembedurl>https://stocktwits.com/BULLNATION1/message/603560053</stembedurl><stembedurl>https://stocktwits.com/Mr_Xray/message/603579405</stembedurl>Biodexa's stock has gained around 57% so far this year, though it is still down more than 80% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks

The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer. 

Equity

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Current Price	$3.27
Prev Close	$3.30
Open	$3.40
Dividend Yield	0.00%
50-Day Moving Average	$4.25
Beta	1.34
Avg. Volume	15,591.54
PE Ratio	-0.03

52-Week High	$96.50
52-Week Low	$2.86
Market Capitalization	$1.49M
EPS (Annual)	-$79.07
Price to Book	1.66
Revenue Per Employee	$0.00

BDRX
Biodexa Pharmaceuticals Plc

Feed

News

Sentiment

Fundamentals

Info

Latest BDRX News

BDRXBiodexa Pharmaceuticals Plc